Omniscope named Nebius semifinalist

Omniscope said on May 23 that it had been named a semifinalist in the 2026 AI Discovery Awards run by AI infrastructure company Nebius. The Barcelona-based startup said the recognition covered its work on decoding the immune system, an area it pitches as useful across health, therapy and research. Nebius’s awards program is focused on startups using artificial intelligence in drug discovery, biotechnology, genomics, healthtech and related fields. The semifinalist list was published this week, with finalists still to come. ### What exactly did Omniscope say it was recognized for? Omniscope said the Nebius shortlist recognized its work on decoding the immune system. On its website, the company says it helps users “see what your immune system is seeing” and describes its platform as a way to “discover your immune system to boost performance, optimize healthspan, and engineer therapy.” The company’s recent materials tie that pitch to immune profiling and AI-driven analysis. Omniscope’s site lists projects and publications focused on T-cell activity, therapy-induced immune responses and immune-age modeling, alongside partnerships in sports medicine, longevity and pharma. ### How big is the Nebius competition? Nebius said 198 startups advanced to the semifinal round from 646 submissions. (omniscope.ai) The company describes AI Discovery Awards 2026 as an annual program for startups using AI to “revolutionize drug discovery, biotechnology, genomics and HealthTech.” Nebius has divided this year’s competition into five categories: BioPharma, Genomics, Digital Health, Medical Devices and Medical Imaging. (omniscope.ai) The awards page says semifinalists were selected after a first round of evaluations. ### Where does Omniscope fit in that field? Nebius said the awards are aimed at healthcare and life-sciences startups, and Omniscope’s public materials place it squarely in that market. (nebius.com) The company says it is building AI-powered immune-decoding tools for applications ranging from therapy design to health optimization. A recent Omniscope application note says its platforms analyze T- and B-cell dynamics to assess vaccine safety, efficacy and duration of protection. (nebius.com) That document describes deep immune profiling as a tool for vaccine research and long-term immune measurement. (omniscope.ai) ### What does being a semifinalist mean in practice? Nebius said semifinalists have advanced through the first screening stage, but they are not yet finalists or winners. The company’s event page says the awards ceremony will be the “grand finale” of a longer selection process and will include a live announcement of winners across the five categories. (cdn.prod.website-files.com) The awards are part of a broader Nebius push into healthcare and life sciences. Nebius says the program is meant to spotlight new technologies, connect startups with investors and support AI-powered healthcare innovation. ### When are the next milestones? Nebius said finalists will be announced in June. Its event page lists the AI Discovery Award Ceremony for Wednesday, July 1, 2026, in London, where winners across the five categories are scheduled to be announced live. (nebius.com) London’s Town Hall Spaces in King’s Cross is the listed venue, and Nebius said semifinalists may register with guaranteed admission for up to two representatives per company. (nebius.com 1) (nebius.com 2)